Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Coxon, Angela ^a   Ziegler, Beth ^a   Kaufman, Stephen ^a   Xu, Man ^a   Wang, Hongyu ^b   Weishuhn, Dawn ^b   Schmidt, Joanna ^a   Sweet, Heather ^b   Starnes, Charlie ^a   Saffran, Douglas ^a   Polverino, Anthony ^c  

^a AMGEN INC   (United States)

^b Amgen British Columbia ^*  (Canada)

^c AMGEN INC   (United States)

Author keywords

Angiogenesis; Cisplatin; Docetaxel; Motesanib; NSCLC; VEGF receptor

Indexed keywords

CD31 ANTIGEN; CISPLATIN; DOCETAXEL; MOTESANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; STAINING; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; GENE EXPRESSION; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; NIACINAMIDE; TAXOIDS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866266429     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-70     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544. 10.1200/JCO.2005.04.4859, 17008692.
3. NCCN clinical practice guidelines in oncology: non-small cell lung cancer v.3 National Comprehensive Cancer Network 2011, Available at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed March 1, 2011, NCCN clinical practice guidelines in oncology: non-small cell lung cancer v.3.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. 10.1056/NEJMoa011954, 11784875.
5. Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:206-217. 10.1513/pats.200807-066LC, 19349490.
6. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ, Landreneau RJ. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8:72-79. 10.1007/s10434-001-0072-y, 11206229.
7. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997, 3:861-865.
8. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000, 82:1427-1432. 10.1054/bjoc.1999.1129, 2363365, 10780522.
9. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998, 115:1007-1014. 10.1016/S0022-5223(98)70398-8, 9605068.
10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234. 10.1200/JCO.2007.14.5466, 19188680.
12. Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer Ther 2009, 9:425-435. 10.1586/era.09.3, 19374597.
13. Rossi A, Maione P, Bareschino MA, Schettino C, Sacco PC, Ferrara ML, Castaldo V, Gridelli C. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr Med Chem 2010, 17:1030-1038. 10.2174/092986710790820589, 20156162.
14. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481. 10.1097/JTO.0b013e318189f551, 19057275.
15. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:1416-1423. 10.1097/JTO.0b013e3181da36f4, 20686429.
16. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180. 10.1016/S1470-2045(10)70087-5, 21277552.
17. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874. 10.1200/JCO.2010.33.4235, 21670455.
18. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128. 10.1016/S1470-2045(09)70364-X, 20022809.
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
21. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051. 10.1200/JCO.2010.33.1280, 3107760, 21483012.
22. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Canc Treat Rev 2010, 36(Suppl 3):S21-S29.
23. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66:8715-8721. 10.1158/0008-5472.CAN-05-4665, 16951187.
24. Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, et al. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res 2009, 15:110-118. 10.1158/1078-0432.CCR-08-1155, 19118038.
25. Starnes C, Coxon A, Scully S, Freeman D, Patel V, Tasker A, Polverino T, Kendall R, Radinsky R. Antitumor activity of AMG 706 alone and in combination with chemotherapy against established human tumor xenograft models in nude mice [abstract]. Proc Am Assoc Canc Res 2006, 47:3780.
26. Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A. Antitumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest 2011, 35:181-190.
27. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42. 10.1056/NEJMoa075853, 18596272.
28. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:2369-2376. 10.1200/JCO.2006.07.8170, 17557949.
29. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801. 10.1200/JCO.2008.18.7815, 19564535.
30. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:279-290. 10.1158/1078-0432.CCR-09-1675, 20028752.
31. Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011, 22:2057-2067. 10.1093/annonc/mdq731, 21321086.
32. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol 2011, 29:CRA7506.
33. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285. 10.1097/JTO.0b013e318206a221, 21252716.
34. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400. 10.1158/0008-5472.CAN-04-4409, 15899831.
35. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
36. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jurgensmeier JM, Wedge SR, Barry ST. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 2007, 6:2198-2208. 10.1158/1535-7163.MCT-07-0142, 17699717.
37. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Canc Chemother Pharmacol 2007, 59:183-195.
38. Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res 2006, 12:1630-1638. 10.1158/1078-0432.CCR-05-2028, 16533791.
39. McLemore TL, Liu MC, Blacker PC, Gregg M, Alley MC, Abbott BJ, Shoemaker RH, Bohlman ME, Litterst CC, Hubbard WC, et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 1987, 47:5132-5140.
40. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 2009, 8:1536-1546. 10.1158/1535-7163.MCT-08-0978, 19509246.
41. Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 2009, 4:161-166. 10.1097/JTO.0b013e318194fae7, 2758160, 19179890.
42. Starnes C, Freeman D, Bush T, Leal J, McDorman K, Coxon A, Patel V, Polverino T, Kendall R, Radinsky R. Antitumor activity of AMG 706, a novel tyrosine kinase inhibitor, in combination with panitumumab, a fully human antibody targeting the EGF receptor against multiple established human tumor xenograft models in nude mice [abstract B73]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 14-18; Philadelphia, PA 2005, 144.
43. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989. 10.1038/nm0901-987, 11533692.
44. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003, 88:1979-1986. 10.1038/sj.bjc.6601005, 2741115, 12799646.
45. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Canc Res Offic J Am Assoc Canc Res 2009, 15:3484-3494.
46. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Canc Res Offic J Am Assoc Canc Res 2010, 16:4990-5001.
47. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007, 6:471-483. 10.1158/1535-7163.MCT-06-0416, 17308046.
48. COSMIC Database, Sanger Institute Distribution of somatic mutations in KRAS 2011, Available at: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bygene&ln=KRAS, COSMIC Database, Sanger Institute.
49. COSMIC Database, Sanger Institute Distribution of somatic mutations in NRAS 2011, Available at: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bygene&ln=NRAS, COSMIC Database, Sanger Institute.
50. COSMIC Database, Sanger Institute Distribution of somatic mutations in NCI-H1650 cells 2011, Available at: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=sample;id=687800. Accessed September 16, COSMIC Database, Sanger Institute.
51. Gong HC, Wang S, Mayer G, Chen G, Leesman G, Singh S, Beer DG. Signatures of drug sensitivity in nonsmall cell lung cancer. Int J Proteomics 2011, 2011:215496. 3200133, 22091388.
52. Li Y, Raffo AJ, Drew L, Mao Y, Tran A, Petrylak DP, Fine RL. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res 2003, 63:1527-1533.
53. Takahashi T, Carbone D, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992, 52:2340-2343.